Pathophysiological role of nitric oxide and adrenomedullin in autism

Basit Öğe Kaydı
dc.authoridYurekli, Muhittin/0000-0002-5830-8564
dc.authoridYanik, Medaim/0000-0001-5936-0017
dc.authoridsivasli, ercan/0000-0001-9719-9906
dc.authorwosidYurekli, Muhittin/B-4414-2016
dc.authorwosidZoroglu, Salih/ABD-8029-2020
dc.authorwosidzoroglu, suleyman s/B-2077-2012
dc.contributor.authorZoroglu, SS
dc.contributor.authorYürekli, M
dc.contributor.authorMeram, I
dc.contributor.authorSögüt, S
dc.contributor.authorTutkun, H
dc.contributor.authorYetkin, Ö
dc.contributor.authorSivasli, E
dc.date.accessioned2024-08-04T20:13:17Z
dc.date.available2024-08-04T20:13:17Z
dc.date.issued2003
dc.departmentİnönü Üniversitesien_US
dc.description.abstractSeveral studies indicate that nitric oxide (NO) is involved in the aetiopathogenesis of many neuropsychiatric disorders such as schizophrenia, bipolar disorder, depression, Alzheimer's disease, Hungtington disease and stroke. Although it has not been investigated yet, several recent studies proposed that NO may have a pathophysiological role in autism. Adrenomedullin (AM), a recently discovered 52-amino acide peptide hormone, induces vasorelaxation by activating adenylate cyclase and also by stimulating NO release. AM immune reactivity is present in the brain consistent with a role as a neurotransmitter. It has been stated that NO and AM do function in the regulation of many neurodevelopmental processes. We hypothesized that NO and AM activities have been affected in autistic patients and aimed to examine these molecules. Twenty-six autistic patients and 22 healthy control subjects were included in this study. AM and total nitrite (a metabolite of NO) levels have been measured in plasma. The mean values of plasma total nitrite and AM levels in the autistic group were significantly higher than control values, respectively (p < 0.001, p = 0.028). There is no correlation between total nitrite and AM levels (r = 0.11, p = 0.31). Certainly, this subject needs much further research investigating autistic patients in earlier periods of life and with subtypes of the disorder. Copyright (C) 2002 John Wiley Sons, Ltd.en_US
dc.identifier.doi10.1002/cbf.989
dc.identifier.endpage60en_US
dc.identifier.issn0263-6484
dc.identifier.issue1en_US
dc.identifier.pmid12579522en_US
dc.identifier.scopus2-s2.0-0037369373en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage55en_US
dc.identifier.urihttps://doi.org/10.1002/cbf.989
dc.identifier.urihttps://hdl.handle.net/11616/93502
dc.identifier.volume21en_US
dc.identifier.wosWOS:000181097100008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJohn Wiley & Sons Ltden_US
dc.relation.ispartofCell Biochemistry and Functionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectautismen_US
dc.subjectpervasive developmental disorderen_US
dc.subjectnitric oxideen_US
dc.subjectadrenomedullinen_US
dc.subjecttotal nitriteen_US
dc.titlePathophysiological role of nitric oxide and adrenomedullin in autismen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu